

April 9th, 2010
MEDRx Co. Ltd.

The LOI has been signed with AnGes MG Inc. on the Licensing-out of the Transdermal Formulation containing NF- κ B Decoy Oligonucleotide

MEDRx Co. Ltd. (MEDRx) promotes R&D of the transdermal formulations to enhance extremely skin permeability of high molecular drug candidates such as nucleic acid and peptide by its unique transdermal formulation technologies, ILTS® (Ionic Liquid Transdermal System), making use of Ionic Liquid, compared with the conventional transdermal technologies.

MEDRx has been developing the new formulation to improve the skin permeability of NF- κ B Decoy Oligonucleotide using its ILTS® technologies with AnGes MG Inc. (AnGes). MEDRx announces that MEDRx formally agreed with AnGes to begin discussions of grant of license with sublicense related to the technology for the transdermal formulation of NF- κ B Decoy Oligonucleotide.

AnGes is developing NF- κ B Decoy Oligonucleotide as an ethical drug for skin disease treatment such as atopic dermatitis and is discussing a joint development with Shionogi & Co., Ltd. as development partners.

